Single dose glucagon (0.5 mg IV bolus) administration in healthy human volunteers is a robust model for assessment of glycogenolysis. Characterisation of the glucose excursion after glucagon challenge

Journal of Pharmacological and Toxicological Methods

Volumn 55, Issue 1, 2007, Pages 86-90

  Lockton, J Andrew ^a   Poucher, Simon M ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Glucagon; Glucose; Healthy volunteers; Insulin; Methods; Type 2 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; PLACEBO; SODIUM CHLORIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; BOLUS INJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCOGENOLYSIS; HUMAN; HUMAN EXPERIMENT; INSULIN BLOOD LEVEL; MALE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NORMAL HUMAN; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; REPRODUCIBILITY; SINGLE DRUG DOSE;

ADULT; BLOOD GLUCOSE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; GLUCAGON; GLYCOGENOLYSIS; HUMANS; MALE; MIDDLE AGED;

EID: 33846015449     PISSN: 10568719     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vascn.2006.03.009     Document Type: Article

References (10)

1. Basu A., Shah P., Nielsen M., Basu R., and Rizza R.A. Effects of type 2 diabetes on the regulation of hepatic glucose metabolism. Journal of Investigative Medicine 52 6 (2004) 366-374
2. Cherrington A.D., Williams P.E., Shulman G.I., and Lacy W.W. Differential time course of glucaong's effect on glycogenolysis and gluconeogenesis in the conscious dog. Diabetes 30 (1981) 180-187
3. Gerich J.E. Physiology of glucose homeostasis. Diabetes, Obesity and Metabolism 2 (2000) 345-350
4. Hundal R.S., and Inzucchi S.E. Metformin: new understandings, new uses. Drugs 63 18 (2003) 1879-1894
5. Magnusson I., Rothman D.L., Gerard D.P., Katz L.D., and Shulman G.I. Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. Diabetes 44 (1995) 185-189
6. Petersen K.F., Cline G.W., Gerard D.P., Magnusson I., Rothman D.L., and Shulman G.I. Contribution of net hepatic glycogen synthesis to disposal of an oral glucose load in humans. Metabolism 50 (2001) 598-601
7. Petersen K.E., and Sullivan J.T. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 44 (2001) 2018-2024
8. Stratton I.M., Adler A.I., Neil H.A.W., Matthews D.R., Manley S.E., Cull C.A., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
9. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS33). Lancet 352 (1998) 837-853
10. Zimmet P., Alberti K.G.M.M., and Shaw J. Global and societal implications of the diabetes epidemic. Nature 414 (2001) 782-787